Chimerix Inc. (NASDAQ:CMRX)’s share price was up 4.9% during trading on Tuesday . The stock traded as high as $5.87 and last traded at $5.81, with a volume of 529,055 shares trading hands. The stock had previously closed at $5.54.
A number of equities analysts recently issued reports on CMRX shares. Piper Jaffray Cos. set a $12.00 price target on shares of Chimerix and gave the stock a “buy” rating in a research note on Thursday, August 18th. Zacks Investment Research raised shares of Chimerix from a “hold” rating to a “buy” rating and set a $4.75 price target for the company in a research note on Wednesday, August 10th. FBR & Co decreased their price target on shares of Chimerix from $9.00 to $8.00 and set a “mkt perform” rating for the company in a research note on Tuesday, August 9th. Finally, JPMorgan Chase & Co. reissued a “hold” rating and issued a $7.00 price target on shares of Chimerix in a research note on Tuesday, August 9th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company. Chimerix presently has an average rating of “Hold” and an average price target of $12.28.
The stock’s market cap is $272.20 million. The company’s 50 day moving average price is $4.62 and its 200-day moving average price is $4.74.
Chimerix (NASDAQ:CMRX) last released its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.12. Chimerix had a negative net margin of 1,356.50% and a negative return on equity of 34.75%. The firm earned $1.80 million during the quarter, compared to analysts’ expectations of $1.98 million. On average, equities analysts forecast that Chimerix Inc. will post ($1.78) EPS for the current year.
In other news, insider M Michelle Berrey purchased 22,417 shares of the company’s stock in a transaction that occurred on Monday, August 29th. The stock was purchased at an average cost of $4.47 per share, with a total value of $100,203.99. Following the purchase, the insider now owns 281,238 shares in the company, valued at $1,257,133.86. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director John M. Leonard sold 5,000 shares of Chimerix stock in a transaction dated Thursday, September 15th. The stock was sold at an average price of $5.03, for a total transaction of $25,150.00. The disclosure for this sale can be found here. Corporate insiders own 10.50% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the company. BlackRock Group LTD raised its stake in shares of Chimerix by 30.2% in the first quarter. BlackRock Group LTD now owns 23,048 shares of the biopharmaceutical company’s stock worth $118,000 after buying an additional 5,344 shares during the last quarter. Royal Bank of Canada raised its stake in shares of Chimerix by 9,017.0% in the first quarter. Royal Bank of Canada now owns 24,160 shares of the biopharmaceutical company’s stock worth $123,000 after buying an additional 23,895 shares during the last quarter. Virginia Retirement Systems ET AL bought a new stake in shares of Chimerix during the second quarter worth $103,000. Raymond James & Associates raised its stake in shares of Chimerix by 6.9% in the second quarter. Raymond James & Associates now owns 27,083 shares of the biopharmaceutical company’s stock worth $106,000 after buying an additional 1,757 shares during the last quarter. Finally, Highbridge Capital Management LLC bought a new stake in shares of Chimerix during the second quarter worth $112,000. 67.21% of the stock is owned by hedge funds and other institutional investors.
Chimerix, Inc (Chimerix) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral antivirals. The Company, based on its lipid conjugate technology, has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development.
Receive News & Ratings for Chimerix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.